Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Ethics

The Ethical Tug-of-War Over Biosimilar Adoption

Karen Ferguson, MS, & Richard L. Allman, MD, MS, FACP, FACR  |  December 9, 2024

The advent of biosimilar medications has offered the promise of significant cost savings for healthcare systems and patients. Biosimilars are highly similar versions of existing biologic drugs, providing a more affordable alternative once the original biologic patent expires. However, the adoption of biosimilars in the U.S. has been hampered by myriad roadblocks, many of which…

The 7 Virtues of Rheumatology We Should Cultivate

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  October 8, 2024

1949 was a momentous year—astronomer Fred Hoyle coined the term Big Bang, the North Atlantic Treaty Organization (NATO) was formed, and Rodgers and Hammerstein’s classic musical South Pacific opened on Broadway.1 Much less recognized was the publication of an essay by Richard Asher, FRCP, titled the “Seven Sins of Medicine.”2 Although it’s over 75 years…

Ethics Forum: The ACR Code in Practice

Prajakta Masurkar, PhD, MPharm, & Charis Meng, MD  |  September 9, 2024

Ethical conduct is the cornerstone of any professional organization, particularly when its decisions have an impact on public health. The ACR recognizes the importance of upholding ethical standards and has established a Code of Ethics to guide its members. Here we explore the practical application of the ACR’s Code of Ethics.1 Manage Potential Conflicts Central…

Ethics Forum: The Current Landscape of Artificial Intelligence in Medicine

Jeanne Gosselin, MD  |  May 6, 2024

A handful of articles on artificial intelligence (AI) have graced the pages of this publication in the past six years, including one by Bharat Kumar, MD, in November 2022. Dr. Kumar highlighted the exciting potential of AI in rheumatology, including machine learning (ML) algorithms for the prediction of response to methotrexate and a predictive model…

Ethics Forum: Mitigation Tips for Health Disparities Among Rural & Indigenous Peoples

Laura Nichols, MD, Lee Graham, MD, & Erdal Diri, MD  |  October 12, 2023

A common case scenario in our practice in North Dakota is a woman with rheumatoid arthritis on methotrexate monotherapy. She is a member of the Sisseton Wahpeton Oyate people and lives 90 miles from our rheumatology clinic. She currently has moderate disease activity, indicating the need for additional treatment. She does not have her own…

In the Wake of Dobbs v. Jackson Women’s Health Organization

Mary Beth Nierengarten  |  May 10, 2023

Since the Supreme Court ruling in June 2022 overturning 50 years of precedent protecting abortion as a constitutional right (Dobbs v. Jackson Women’s Health Organization), states are enacting and implementing new laws to regulate abortion, and medical organizations and healthcare providers are assuming the large task of understanding what the new laws mean for their…

Conflicts of Interest in Guideline Development: What to Do When Everyone Has a Conflict

Anne R. Bass, MD  |  March 12, 2023

Avoiding real and apparent conflicts of interest is a fundamental principle of guideline development, but what should we do when every thought leader is conflicted? An example of this conundrum in rheumatology has been the ACR’s ongoing effort to establish guidelines for the management of lupus nephritis, which has been stymied by the fact that…

Ethics Forum: Has the Patient Asked for More Than Can Be Ethically Allowed?

Richard L. Allman, MD, MS, FACP, FACR  |  November 10, 2022

The patient, a 76-year-old woman, had very active polyarticular rheumatoid arthritis (RA), despite triple therapy with conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), low-dose corticosteroids and occasional intra-articular injections—the latter providing only transient symptomatic relief. She had elevated inflammatory markers and a 28-joint Disease Activity Score (DAS-28) score of 7.4.  Because of the severity of her…

Speak Out Rheum: To Prescribe Is Humane (Unless You’re In Texas)

Raymond Scalettar, MD, DSc  |  November 7, 2022

You are a rheumatologist in Texas. You are very well trained. Your mentors included some of the leaders in rheumatology, and you are respected by your colleagues and your patients. You know the devastation of untreated rheumatoid arthritis and lupus. A young woman with recent onset of systemic lupus erythematosus is your new patient. You…

Where Do Rules End & Compassion Begin?

Joel M. Kremer, MD, MACR  |  September 5, 2022

My long-standing patient with CRST syndrome (i.e., calcinosis cutis, Raynaud’s phenomenon, sclerodactyly and telangiectasia) had been losing ground over the past 18 months. BL was 54 and had developed restrictive pulmonary disease without radiographic pulmonary infiltrates. Her mean right heart pressures were moderately elevated by ultrasonography. But the greatest impact on her quality of life…

  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences